These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17092665)

  • 41. [Hormone replacement therapy: the pros].
    Jamin C; Madelenat P
    Gynecol Obstet Fertil; 2008 Jan; 36(1):98-103. PubMed ID: 18248839
    [No Abstract]   [Full Text] [Related]  

  • 42. Are the serum levels of sCD40L modified by raloxifene in postmenopausal women?
    Oviedo PJ; Hermenegildo C; Novella S; Tarín JJ; Cano A
    Eur J Obstet Gynecol Reprod Biol; 2008 Oct; 140(2):296-7. PubMed ID: 18583017
    [No Abstract]   [Full Text] [Related]  

  • 43. [Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
    Gorai I;
    Clin Calcium; 2007 Jul; 17(7):1090-6. PubMed ID: 17607077
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis.
    Jochems C; Islander U; Kallkopf A; Lagerquist M; Ohlsson C; Carlsten H
    Arthritis Rheum; 2007 Oct; 56(10):3261-70. PubMed ID: 17907171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Apoptosis in raloxifene-treated postmenopausal women.
    Biri A; Yurtcu E; Ciftci B; Korucuoğlu U; Ilhan MN; Ergun MA; Gursoy R; Biberoglu K
    Cell Biol Int; 2007 Mar; 31(3):289-92. PubMed ID: 17175181
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
    Silverman SL; Shen W; Minshall ME; Xie S; Moses KH
    J Rheumatol; 2007 Jan; 34(1):140-4. PubMed ID: 17216681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause?
    Manson JE; Bassuk SS
    Am J Epidemiol; 2007 Sep; 166(5):511-7. PubMed ID: 17646204
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Re: "invited commentary: Hormone therapy and risk of coronary heart disease-why renew the focus on the early years of menopause?".
    Rosenberg L
    Am J Epidemiol; 2007 Dec; 166(12):1480-1; author reply 1481-2. PubMed ID: 17993654
    [No Abstract]   [Full Text] [Related]  

  • 49. Re: "invited commentary: Hormone therapy and risk of coronary heart disease--why renew the focus on the early years of menopause?".
    Dören M; Greiser EM
    Am J Epidemiol; 2007 Dec; 166(12):1479-80; author reply 1481-2. PubMed ID: 17977898
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of raloxifene treatment on osteocyte apoptosis in postmenopausal women.
    van Essen HW; Holzmann PJ; Blankenstein MA; Lips P; Bravenboer N
    Calcif Tissue Int; 2007 Sep; 81(3):183-90. PubMed ID: 17676256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The medical management of menopause: to treat or not to treat?
    Barlow DH
    Ann N Y Acad Sci; 2008 Apr; 1127():134-9. PubMed ID: 18443341
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.
    Adomaityte J; Farooq M; Qayyum R
    Thromb Haemost; 2008 Feb; 99(2):338-42. PubMed ID: 18278183
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Estrogen ring use for genitourinary atrophy and menopausal symptomatology.
    Thacker HL
    Geriatrics; 2004 May; 59(5):34, 36-7. PubMed ID: 15152734
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of hormone replacement therapy on connective tissue: why is this important?
    Calleja-Agius J; Brincat MP
    Best Pract Res Clin Obstet Gynaecol; 2009 Feb; 23(1):121-7. PubMed ID: 19095501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Menopause].
    Lopes P; Trémollières F
    Rev Prat; 2012 Mar; 62(3):399-401, 403, 405-6. PubMed ID: 22515005
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical relevance of the HERS trial.
    Gambacciani M; Rosano GM; Monteleone P; Fini M; Genazzani AR
    Lancet; 2002 Aug; 360(9333):641. PubMed ID: 12241954
    [No Abstract]   [Full Text] [Related]  

  • 58. [Clinical experiences with a new steroid-free preparation for management of the postmenopausal symptom complex].
    Kress D; Philipp E
    Med Monatsschr; 1975 Jun; 29(6):272-4. PubMed ID: 772406
    [No Abstract]   [Full Text] [Related]  

  • 59. The healing properties of exercise.
    Pines A; Fisman EZ
    Menopause; 2006; 13(4):544-5. PubMed ID: 16837873
    [No Abstract]   [Full Text] [Related]  

  • 60. [The dilemma of the clinical trial: what does it prove?].
    Fülgraff G
    Klin Wochenschr; 1989 Jul; 67(14):737-8. PubMed ID: 2770188
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.